Objective:To systematically review the efficacy and clinical safety of Qizhi Weitong Granules(气滞胃痛颗粒)(QZWT)in the treatment of irritable bowel syndrome with predominant constipation(IBS-C).Methods:Randomized con...Objective:To systematically review the efficacy and clinical safety of Qizhi Weitong Granules(气滞胃痛颗粒)(QZWT)in the treatment of irritable bowel syndrome with predominant constipation(IBS-C).Methods:Randomized controlled trials(RCTs)of QZWT in patients with IBS-C were retrieved from Pub Med,EMBASE,Cochrane Library,China National Knowledge Infrastructure(CNKI),Wanfang,Chinese Scientific Journals Database(VIP),and Chinese Biological Medical Database(CBM)from inception to December 3,2022.Conventional meta-analysis with random-effects model or fixed-effects model and trial sequential analysis(TSA)were performed by Review Manager 5.4,Stata and TSA software.Results:A total of 4 RCTs and 368 patients with IBS-C were included in this study.The findings of the meta-analysis indicated that the cure and efficacy rate of the experimental group was significantly higher than that of the control group[RR=2.19;(95%CI,1.35–3.55),P<0.01;RR=1.14;(95%CI,1.03–1.27),P<0.05],while the result of Bristol Score was negative.The funnel plot was probably symmetry,and the P value was>0.05 in the Egger test,which confirmed the nonexistence of significant publication bias in this outcome.TSA showed the cumulative z-value crossed the traditional threshold and TSA threshold,while it didn't get to the required information size.Finally,2 studies reported adverse events after QZWT treatment,including 3 cases of diarrhea.No serious adverse events were reported.Conclusion:QZWT was an effective and safe complementary therapy in the treatment of IBS-C with no obvious adverse reactions.TSA analysis confirmed our meta-analysis results.Therefore,QZWT may be a potential candidate for the treatment of IBS-C.However,due to the limited quality of current studies,more long-term,randomized,double-blinded clinical trials are needed in future studies.展开更多
OBJECTIVE:To investigate the therapeutic action and mechanism of the Qizhi Jiangtang capsule(芪蛭降糖胶囊,QZJT)on diabetic kidney disease(DKD)treatment.METHODS:This experiment used db/db mice and podocytes(MPC5)to dev...OBJECTIVE:To investigate the therapeutic action and mechanism of the Qizhi Jiangtang capsule(芪蛭降糖胶囊,QZJT)on diabetic kidney disease(DKD)treatment.METHODS:This experiment used db/db mice and podocytes(MPC5)to develop DKD model.Evaluation of the effect of the QZJT on db/db mice by testing urine and blood biochemical parameters(24-h urinary albumin,serum creatinine,blood urine nitrogen),pathological kidney injury,and podocyte integrity.Moreover,autophagosomes in podocytes of DKD mice and cultured podocytes were detected using electron microscopy.Additionally,Western blotting was applied to detect the expression of podocyte marker protein(podocin),autophagy-associated proteins,and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin(PI3K/AKT/mTOR)signaling pathway changes in vivo and in vitro.RESULTS:QZJT significantly reduced urine protein,blood nitrogen urea,and serum creatinine and showed histological restoration of renal tissues.QZJT also significantly improved the down-regulation of podocin and foot fusion and effacement in db/db mice.QZJT increased autophagic vesicles in mice and cultured podocytes.QZJT also upregulated microtubuleassociated protein 1 light chain 3-II(LC3-II)/(LC3-I)and Beclin-1 and downregulated phosphorylated-PI3K(pPI3K),p-AKT,and p-mTOR in db/db mice and MPC5 cells.However,autophagy inhibitor 3-methyladenine partially alleviated the above effects in MPC5 cells.CONCLUSIONS:These results showed that the QZJT can enhance podocyte autophagy and ameliorate podocyte injury in DKD by inhibiting the PI3K/AKT/mTOR signaling pathway.展开更多
目的探讨果蝇双翅边缘缺刻同源基因(Notch)信号通路在慢性阻塞性肺疾病(COPD)辅助性T细胞1(Helper T cells 1,Th1)和辅助性T细胞2(Helper T cells 2,Th2)失衡中的作用及芪蛭皱肺颗粒的干预机制。方法70只Wistar大鼠随机挑选10只作为空...目的探讨果蝇双翅边缘缺刻同源基因(Notch)信号通路在慢性阻塞性肺疾病(COPD)辅助性T细胞1(Helper T cells 1,Th1)和辅助性T细胞2(Helper T cells 2,Th2)失衡中的作用及芪蛭皱肺颗粒的干预机制。方法70只Wistar大鼠随机挑选10只作为空白对照组,其余大鼠均采用香烟烟雾(CS)联合气管滴注脂多糖(Lipopolysaccharide,LPS)法建立COPD模型,空白对照组及造模组各随机挑选3只大鼠验证造模是否成功。造模结束进行灌胃给药干预,造模组大鼠随机分为模型对照组、阳性对照组(67.5μg·kg^(-1))及芪蛭皱肺颗粒高中低剂量组(3.24、1.62、0.81 g·kg^(-1)),分别给予生理盐水、醋酸地塞米松混悬液、芪蛭皱肺高、中、低剂量混悬液进行灌胃干预,空白对照组同模型对照组,灌胃等体积生理盐水。经28天造模及28天治疗后,采用动物肺功能测试系统检测吸气峰流速(Peak Inspiratory Flow,PIF)和呼气峰流速(Peak Expiratory Flow,PEF),处死大鼠提取肺脏、脾脏、血清及支气管肺泡灌洗液(BALF),苏木素-伊红(HE)染色评价肺组织病理变化,酶联免疫吸附实验法(ELISA)测定血清及BALF中肿瘤坏死因子-α(TNF-α)含量,流式细胞仪检测脾脏Th1/Th2细胞水平,免疫组织化学法(Immunohistochemistry,IHC)及蛋白免疫印迹法(Western blot)检测肺组织Notch1、Hes家族发状分裂相关增强子1(Hes1)、Hey家族发状分裂相关增强子1(Hey1)蛋白水平,实时荧光定量聚合酶链式反应(Real-time PCR,RT-PCR)检测肺组织Notch1、Hes1、Hey1基因表达水平。结果与空白对照组比较,模型对照组大鼠肺功能显著降低(P<0.05),肺组织出现炎性细胞浸润、支气管结构破坏等病变,血清及BALF中TNF-α含量显著升高(P<0.05),脾Th1细胞百分比显著降低(P<0.05),Th2细胞百分比显著升高(P<0.05),肺组织Notch1、Hes1、Hey1蛋白及mRNA表达显著升高(P<0.05),差异均具有统计学意义;与模型对照组比较,各给药组大鼠肺功能显著升高(P<0.05),肺组织病理损伤均有所减轻,血清及BALF中TNF-α含量显著降低(P<0.05),脾Th1细胞百分比显著升高(P<0.05),Th2细胞百分比显著降低(P<0.05),肺组织Notch1、Hes1、Hey1蛋白及mRNA表达显著降低(P<0.05),差异均具有统计学意义。结论芪蛭皱肺颗粒通过抑制Notch信号通路调节Th1/Th2平衡,从而改善COPD大鼠肺功能及病理损伤,影响其免疫功能。展开更多
目的探讨通调针刺法联合芪蛭三七汤治疗脑卒中后运动障碍的效果及对血清脑源性神经营养因子(brain derived neurotrophic factor,BDNF)、神经肽Y(neuropeptide,NPY)水平的影响。方法选取2019年9月—2022年8月医院收治的102例脑卒中后运...目的探讨通调针刺法联合芪蛭三七汤治疗脑卒中后运动障碍的效果及对血清脑源性神经营养因子(brain derived neurotrophic factor,BDNF)、神经肽Y(neuropeptide,NPY)水平的影响。方法选取2019年9月—2022年8月医院收治的102例脑卒中后运动障碍患者,依照随机数表法分为研究组(n=51例)和对照组(n=51例),对照组采用基础康复训练治疗,研究组另给予通调针刺法联合芪蛭三七汤治疗,比较两组患者中医症状评分,临床疗效,Fugl-Meyer运动功能量表(Fugl Meyer Motor Function Assessment,FMA)评分、Berg平衡量表(Berg Balance Scale,BBS)评分、改良Barthel指数、美国国立卫生研究院卒中量表(National Institutes of Health Stroke Scale,NIHSS)评分,血清BDNF、NPY水平及不良反应。结果治疗后,两组患者半身不遂、偏身障碍、意识模糊、口舌歪斜、气短乏力、手足肿胀评分均降低(P<0.05),且研究组半身不遂、偏身障碍、意识模糊、口舌歪斜、气短乏力、手足肿胀评分均低于对照组(P<0.05);研究组总有效率高于对照组,差异有统计学意义(P<0.05);治疗后,两组患者FMA评分和BBS评分均升高(P<0.05),且研究组更高(P<0.05);治疗后,两组患者改良Barthel指数均升高(P<0.05),且研究组更高(P<0.05),两组NIHSS评分均降低(P<0.05),且研究组更低,差异有统计学意义(P<0.05);治疗后,两组血清BDNF水平均升高(P<0.05),且研究组更高,差异有统计学意义(P<0.05),两组血清NPY水平均降低(P<0.05),且研究组更低,差异有统计学意义(P<0.05);不良反应发生率比较,差异无统计学意义(P>0.05)。结论通调针刺法联合芪蛭三七汤用于治疗脑卒中后运动障碍患者疗效确切,能够改善运动障碍及BDNF、NPY水平。展开更多
基金supported by National Natural Science Foundation of China:International (regional)cooperation and exchange project (81820108033)China Academy of Chinese Medical Sciences Youth Talent Project (ZZ14-YQ-020)。
文摘Objective:To systematically review the efficacy and clinical safety of Qizhi Weitong Granules(气滞胃痛颗粒)(QZWT)in the treatment of irritable bowel syndrome with predominant constipation(IBS-C).Methods:Randomized controlled trials(RCTs)of QZWT in patients with IBS-C were retrieved from Pub Med,EMBASE,Cochrane Library,China National Knowledge Infrastructure(CNKI),Wanfang,Chinese Scientific Journals Database(VIP),and Chinese Biological Medical Database(CBM)from inception to December 3,2022.Conventional meta-analysis with random-effects model or fixed-effects model and trial sequential analysis(TSA)were performed by Review Manager 5.4,Stata and TSA software.Results:A total of 4 RCTs and 368 patients with IBS-C were included in this study.The findings of the meta-analysis indicated that the cure and efficacy rate of the experimental group was significantly higher than that of the control group[RR=2.19;(95%CI,1.35–3.55),P<0.01;RR=1.14;(95%CI,1.03–1.27),P<0.05],while the result of Bristol Score was negative.The funnel plot was probably symmetry,and the P value was>0.05 in the Egger test,which confirmed the nonexistence of significant publication bias in this outcome.TSA showed the cumulative z-value crossed the traditional threshold and TSA threshold,while it didn't get to the required information size.Finally,2 studies reported adverse events after QZWT treatment,including 3 cases of diarrhea.No serious adverse events were reported.Conclusion:QZWT was an effective and safe complementary therapy in the treatment of IBS-C with no obvious adverse reactions.TSA analysis confirmed our meta-analysis results.Therefore,QZWT may be a potential candidate for the treatment of IBS-C.However,due to the limited quality of current studies,more long-term,randomized,double-blinded clinical trials are needed in future studies.
基金National Natural Science Foundation of China Project:Experimental Research on Podocyte Autophagy of Diabetic Nephropathy Regulated by Qizhi Jiangtang Capusul(No.81874440)Natural Science Foundation of Shandong Province Project:Curcumin Ameliorates Diabetic Nephropathy via Regulating the Intestinal Barrier-Inflammation“cross-talk”(ZR2020QH063)。
文摘OBJECTIVE:To investigate the therapeutic action and mechanism of the Qizhi Jiangtang capsule(芪蛭降糖胶囊,QZJT)on diabetic kidney disease(DKD)treatment.METHODS:This experiment used db/db mice and podocytes(MPC5)to develop DKD model.Evaluation of the effect of the QZJT on db/db mice by testing urine and blood biochemical parameters(24-h urinary albumin,serum creatinine,blood urine nitrogen),pathological kidney injury,and podocyte integrity.Moreover,autophagosomes in podocytes of DKD mice and cultured podocytes were detected using electron microscopy.Additionally,Western blotting was applied to detect the expression of podocyte marker protein(podocin),autophagy-associated proteins,and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin(PI3K/AKT/mTOR)signaling pathway changes in vivo and in vitro.RESULTS:QZJT significantly reduced urine protein,blood nitrogen urea,and serum creatinine and showed histological restoration of renal tissues.QZJT also significantly improved the down-regulation of podocin and foot fusion and effacement in db/db mice.QZJT increased autophagic vesicles in mice and cultured podocytes.QZJT also upregulated microtubuleassociated protein 1 light chain 3-II(LC3-II)/(LC3-I)and Beclin-1 and downregulated phosphorylated-PI3K(pPI3K),p-AKT,and p-mTOR in db/db mice and MPC5 cells.However,autophagy inhibitor 3-methyladenine partially alleviated the above effects in MPC5 cells.CONCLUSIONS:These results showed that the QZJT can enhance podocyte autophagy and ameliorate podocyte injury in DKD by inhibiting the PI3K/AKT/mTOR signaling pathway.
文摘目的探讨通调针刺法联合芪蛭三七汤治疗脑卒中后运动障碍的效果及对血清脑源性神经营养因子(brain derived neurotrophic factor,BDNF)、神经肽Y(neuropeptide,NPY)水平的影响。方法选取2019年9月—2022年8月医院收治的102例脑卒中后运动障碍患者,依照随机数表法分为研究组(n=51例)和对照组(n=51例),对照组采用基础康复训练治疗,研究组另给予通调针刺法联合芪蛭三七汤治疗,比较两组患者中医症状评分,临床疗效,Fugl-Meyer运动功能量表(Fugl Meyer Motor Function Assessment,FMA)评分、Berg平衡量表(Berg Balance Scale,BBS)评分、改良Barthel指数、美国国立卫生研究院卒中量表(National Institutes of Health Stroke Scale,NIHSS)评分,血清BDNF、NPY水平及不良反应。结果治疗后,两组患者半身不遂、偏身障碍、意识模糊、口舌歪斜、气短乏力、手足肿胀评分均降低(P<0.05),且研究组半身不遂、偏身障碍、意识模糊、口舌歪斜、气短乏力、手足肿胀评分均低于对照组(P<0.05);研究组总有效率高于对照组,差异有统计学意义(P<0.05);治疗后,两组患者FMA评分和BBS评分均升高(P<0.05),且研究组更高(P<0.05);治疗后,两组患者改良Barthel指数均升高(P<0.05),且研究组更高(P<0.05),两组NIHSS评分均降低(P<0.05),且研究组更低,差异有统计学意义(P<0.05);治疗后,两组血清BDNF水平均升高(P<0.05),且研究组更高,差异有统计学意义(P<0.05),两组血清NPY水平均降低(P<0.05),且研究组更低,差异有统计学意义(P<0.05);不良反应发生率比较,差异无统计学意义(P>0.05)。结论通调针刺法联合芪蛭三七汤用于治疗脑卒中后运动障碍患者疗效确切,能够改善运动障碍及BDNF、NPY水平。
